Search

Your search keyword '"Guren, Tormod Kyrre"' showing total 127 results
Start Over Author "Guren, Tormod Kyrre"

Refine your results

more »

more »

more »
127 results on '"Guren, Tormod Kyrre"'

2. Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study

Author

Marabelle, Aurelien, Cassier, Philippe A, Fakih, Marwan, Kao, Steven, Nielsen, Dorte, Italiano, Antoine, Guren, Tormod Kyrre, van Dongen, Marloes G J, Spencer, Kristen, Bariani, Giovanni Mendonca, Ascierto, Paolo A, Santoro, Armando, Shah, Manisha, Asselah, Jamil, Iqbal, Syma, Takahashi, Shunji, Piha-Paul, Sarina A, Ott, Patrick A, Chatterjee, Arkendu, Jin, Fan, Norwood, Kevin, and Delord, Jean-Pierre

Published
2022
Full Text
View/download PDF

11. Pembrolizumab for previously treated advanced anal squamous cell carcinoma:results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study

Author

Marabelle, Aurelien, Cassier, Philippe A., Fakih, Marwan, Kao, Steven, Nielsen, Dorte, Italiano, Antoine, Guren, Tormod Kyrre, van Dongen, Marloes G.J., Spencer, Kristen, Bariani, Giovanni Mendonca, Ascierto, Paolo A., Santoro, Armando, Shah, Manisha, Asselah, Jamil, Iqbal, Syma, Takahashi, Shunji, Piha-Paul, Sarina A., Ott, Patrick A., Chatterjee, Arkendu, Jin, Fan, Norwood, Kevin, Delord, Jean Pierre, Marabelle, Aurelien, Cassier, Philippe A., Fakih, Marwan, Kao, Steven, Nielsen, Dorte, Italiano, Antoine, Guren, Tormod Kyrre, van Dongen, Marloes G.J., Spencer, Kristen, Bariani, Giovanni Mendonca, Ascierto, Paolo A., Santoro, Armando, Shah, Manisha, Asselah, Jamil, Iqbal, Syma, Takahashi, Shunji, Piha-Paul, Sarina A., Ott, Patrick A., Chatterjee, Arkendu, Jin, Fan, Norwood, Kevin, and Delord, Jean Pierre

Abstract

Background: Outcomes in advanced anal squamous cell carcinoma are poor, with few treatment options and controlled clinical trials. We evaluated the efficacy and safety of pembrolizumab in patients with advanced anal squamous cell carcinoma (cohort A) from the phase 2 KEYNOTE-158 study. Methods: Eligible patients enrolled in the ongoing non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study, which was done across 38 centres worldwide, were aged 18 years or older; had histologically or cytologically confirmed advanced or metastatic anal squamous cell carcinoma; had previous failure of or intolerance to standard therapy or no standard therapy options; and had a PD-L1-evaluable tissue sample. Patients received pembrolizumab 200 mg intravenously every 3 weeks for 2 years, or until disease progression, unacceptable toxicity, investigator's decision to withdraw the patient from the study, or withdrawal of patient consent. The primary endpoint was objective response, as assessed by Response Evaluation Criteria in Solid Tumors version 1.1. Efficacy and safety analyses included all patients who received at least one dose of pembrolizumab. The trial is registered with ClinicalTrials.gov, NCT02628067. Findings: Between March 3, 2016, and July 23, 2018, 163 patients were screened, of whom 112 were enrolled and treated in the anal cancer cohort. 91 (81%) patients were female, 104 (93%) had M1 disease, and 75 (67%) had PD-L1-positive tumours. The median time from first dose to data cutoff (June 27, 2019) was 34·7 months (IQR 32·5–36·4). 12 (11%, 95% CI 6–18) patients had an objective response, including 11 (15%, 8–25) of 75 patients with PD-L1-positive tumours and one (3%; 0–17) of 30 patients with PD-L1-negative tumours. 68 (61%) patients had treatment-related adverse events (20 [18%] patients had grade 3–4 adverse events), the most common of which were fatigue (17 patients), diarrhoea (13), hypothyroidism (13), and nausea (13). Serious treatment-related adverse e

Published
2022

12. Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment

Author

Aamdal, Elin, Skovlund, Eva, Jacobsen, Kari Dolven, Straume, Oddbjørn, Kersten, Christian, Herlofsen, Oluf, Karlsen, Jarle, Hussain, Israr, Amundsen, Anita, Dalhaug, Astrid, Nyakas, Marta Sølvi, Hagene, Kirsten Thorin, Holmsen, Kjersti, Aamdal, Steinar, Kaasa, Stein, Guren, Tormod Kyrre, and Kyte, Jon A

Abstract

Background: We have previously reported that the safety and efficacy of ipilimumab in real-world patients with metastatic melanoma were comparable to clinical trials. Few studies have explored health-related quality of life (HRQL) in real-world populations receiving checkpoint inhibitors. This study reports HRQL in real-world patients receiving ipilimumab and assesses the prognostic value of patient-reported outcome measures. Patients and methods: Ipi4 (NCT02068196) was a prospective, multicentre, interventional phase IV trial. Real-world patients (N = 151) with metastatic melanoma were treated with ipilimumab 3 mg/kg intravenously as labelled. HRQL was assessed by the European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire at baseline and after 10-12 weeks. Results: The European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire was completed by 93% (141/151 patients) at baseline, and by 82% at 10-12 weeks. Poor performance status and elevated C-reactive protein (CRP) were associated with worse baseline HRQL. Clinically relevant and statistically significant deteriorations in HRQL from baseline to weeks 10-12 were reported (P

Published
2022

13. First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours

Author

Robbrecht, Debbie, primary, Jungels, Christiane, additional, Sorensen, Morten Mau, additional, Spanggaard, Iben, additional, Eskens, Ferry, additional, Fretland, Signe Ø, additional, Guren, Tormod Kyrre, additional, Aftimos, Philippe, additional, Liberg, David, additional, Svedman, Christer, additional, Thorsson, Lars, additional, Steeghs, Neeltje, additional, and Awada, Ahmad, additional

Published
2021
Full Text
View/download PDF

14. Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer

Author

Hamfjord, Julian, Guren, Tormod Kyrre, Glimelius, Bengt, Sorbye, Halfdan, Pfeiffer, Per, Dajani, Olav, Lingjaerde, Ole Christian, Tveit, Kjell Magne, Pallisgaard, Niels, Spindler, Karen-Lise Garm, and Kure, Elin H.

Subjects
carbohydrate antigen 19&#8208, tumour-specific circulating cell-free DNA, Cancer och onkologi, carcinoembryonic antigen, Cancer and Oncology, colorectal cancer, blood biomarkers, free DNA, carbohydrate antigen 19-9, specific circulating cell&#8208, tumour&#8208
Abstract

Detection of tumour-specific circulating cell-free DNA in plasma (ctDNA) fails in a significant number of cases depending on the clinical context. The primary aim was to investigate clinicopathological factors associated with detection of ctDNA in patients with RAS-/BRAF-mutated metastatic colorectal cancer (mCRC) prior to first-line therapy. A secondary aim was to evaluate the prognostic impact of ctDNA compared to other biomarkers. Patients were included from the NORDIC-VII study (N = 253). ctDNA was sampled prior to treatment and analysed for hotspot tissue mutations (KRAS, NRAS, and BRAF) using droplet digital PCR. Multivariable regression models were constructed to predict the probability of mutation detection and survival. Increasing radiological size of target lesions by increments of 1 cm (odds ratio [OR] = 1.18; 95% confidence interval [CI] 1.09-1.27; P

Published
2021
Full Text
View/download PDF

15. Clinicopathological factors associated with tumour‐specific mutation detection in plasma of patients withRAS‐mutated orBRAF‐mutated metastatic colorectal cancer

Author

Hamfjord, Julian, primary, Guren, Tormod Kyrre, additional, Glimelius, Bengt, additional, Sorbye, Halfdan, additional, Pfeiffer, Per, additional, Dajani, Olav, additional, Lingjærde, Ole Christian, additional, Tveit, Kjell Magne, additional, Pallisgaard, Niels, additional, Spindler, Karen‐Lise Garm, additional, and Kure, Elin H., additional

Published
2021
Full Text
View/download PDF

16. Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial

Author

Aamdal, Elin, primary, Inderberg, Else Marit, additional, Ellingsen, Espen Basmo, additional, Rasch, Wenche, additional, Brunsvig, Paal Fredrik, additional, Aamdal, Steinar, additional, Heintz, Karen-Marie, additional, Vodák, Daniel, additional, Nakken, Sigve, additional, Hovig, Eivind, additional, Nyakas, Marta, additional, Guren, Tormod Kyrre, additional, and Gaudernack, Gustav, additional

Published
2021
Full Text
View/download PDF

17. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

Author

Tabernero, Josep, primary, Grothey, Axel, additional, Van Cutsem, Eric, additional, Yaeger, Rona, additional, Wasan, Harpreet, additional, Yoshino, Takayuki, additional, Desai, Jayesh, additional, Ciardiello, Fortunato, additional, Loupakis, Fotios, additional, Hong, Yong Sang, additional, Steeghs, Neeltje, additional, Guren, Tormod Kyrre, additional, Arkenau, Hendrik-Tobias, additional, Garcia-Alfonso, Pilar, additional, Elez, Elena, additional, Gollerkeri, Ashwin, additional, Maharry, Kati, additional, Christy-Bittel, Janna, additional, and Kopetz, Scott, additional

Published
2021
Full Text
View/download PDF

18. Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer

Author

Brunsvig, Paal F., primary, Guren, Tormod Kyrre, additional, Nyakas, Marta, additional, Steinfeldt-Reisse, Claudius H., additional, Rasch, Wenche, additional, Kyte, Jon Amund, additional, Juul, Hedvig Vidarsdotter, additional, Aamdal, Steinar, additional, Gaudernack, Gustav, additional, and Inderberg, Else Marit, additional

Published
2020
Full Text
View/download PDF

19. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).

Author

Kopetz, Scott, primary, Grothey, Axel, additional, Van Cutsem, Eric, additional, Yaeger, Rona, additional, Wasan, Harpreet Singh, additional, Yoshino, Takayuki, additional, Desai, Jayesh, additional, Ciardiello, Fortunato, additional, Loupakis, Fotios, additional, Hong, Yong Sang, additional, Steeghs, Neeltje, additional, Guren, Tormod Kyrre, additional, Arkenau, Hendrik-Tobias, additional, Garcia-Alfonso, Pilar, additional, Gollerkeri, Ashwin, additional, Maharry, Kati, additional, Christy-Bittel, Janna, additional, and Tabernero, Josep, additional

Published
2020
Full Text
View/download PDF

20. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).

Author

Kopetz, Scott, primary, Grothey, Axel, additional, Van Cutsem, Eric, additional, Yaeger, Rona, additional, Wasan, Harpreet Singh, additional, Yoshino, Takayuki, additional, Desai, Jayesh, additional, Ciardiello, Fortunato, additional, Loupakis, Fotios, additional, Hong, Yong Sang, additional, Steeghs, Neeltje, additional, Guren, Tormod Kyrre, additional, Arkenau, Hendrik-Tobias, additional, Garcia-Alfonso, Pilar, additional, Gollerkeri, Ashwin, additional, Maharry, Kati, additional, Christy-Bittel, Janna, additional, Keir, Christopher Hunt, additional, Pickard, Michael D, additional, and Tabernero, Josep, additional

Published
2020
Full Text
View/download PDF

21. A phase I/IIa clinical trial investigating the therapeutic cancer vaccine UV1 in combination with ipilimumab in patients with malignant melanoma: Four-year survival update.

Author

Ellingsen, Espen Basmo, primary, Aamdal, Elin, additional, Inderberg, Else Marit, additional, Rasch, Wenche, additional, Brunsvig, Paal, additional, Aamdal, Steinar, additional, Hovig, Eivind, additional, Nyakas, Marta, additional, Guren, Tormod Kyrre, additional, and Gaudernack, Gustav, additional

Published
2020
Full Text
View/download PDF

22. Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study.

Author

Marabelle, Aurelien, primary, Cassier, Philippe Alexandre, additional, Fakih, Marwan, additional, Guren, Tormod Kyrre, additional, Italiano, Antoine, additional, Kao, Steven Chuan-Hao, additional, Nielsen, Dorte, additional, Ascierto, Paolo Antonio, additional, Bariani, Giovanni M., additional, Santoro, Armando, additional, Shah, Manisha H., additional, Asselah, Jamil, additional, El-Khoueiry, Anthony B., additional, Spencer, Kristen Renee, additional, Takahashi, Shunji, additional, Chatterjee, Arkendu, additional, Jin, Fan, additional, Norwood, Kevin, additional, and Delord, Jean-Pierre, additional

Published
2020
Full Text
View/download PDF

24. Results from a first-in-man, open label, safety and tolerability trial of CAN04 (nidanilimab), a fully humanized monoclonal antibody against the novel antitumor target, IL1RAP, in patients with solid tumor malignancies.

Author

Awada, Ahmad, primary, Eskens, Ferry, additional, Robbrecht, Debbie, additional, Lassen, Ulrik Niels, additional, Soerensen, Morten Mau, additional, Steeghs, Neeltje, additional, Jungels, Christiane, additional, Aftimos, Philippe Georges, additional, Fretland, Signe Øien, additional, Thorsson, Lars, additional, and Guren, Tormod Kyrre, additional

Published
2019
Full Text
View/download PDF

25. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.

Author

Tabernero, Josep, Grothey, Axel, Van Cutsem, Eric, Yaeger, Rona, Wasan, Harpreet, Yoshino, Takayuki, Desai, Jayesh, Ciardiello, Fortunato, Loupakis, Fotios, Hong, Yong Sang, Steeghs, Neeltje, Guren, Tormod Kyrre, Arkenau, Hendrik-Tobias, Garcia-Alfonso, Pilar, Elez, Elena, Gollerkeri, Ashwin, Maharry, Kati, Christy-Bittel, Janna, and Kopetz, Scott

Published
2021
Full Text
View/download PDF

28. Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer:a BRAF-mutant subset with high CA 19-9 level and poor outcome

Author

Thomsen, Maria, Skovlund, Eva, Sorbye, Halfdan, Bolstad, Nils, Nustad, Kjell Johannes, Glimelius, Bengt, Pfeiffer, Per, Kure, Elin H, Johansen, Julia S, Tveit, Kjell Magne, Christoffersen, Thoralf, Guren, Tormod Kyrre, Thomsen, Maria, Skovlund, Eva, Sorbye, Halfdan, Bolstad, Nils, Nustad, Kjell Johannes, Glimelius, Bengt, Pfeiffer, Per, Kure, Elin H, Johansen, Julia S, Tveit, Kjell Magne, Christoffersen, Thoralf, and Guren, Tormod Kyrre

Abstract

BACKGROUND: Mutation status of RAS and BRAF, as well as serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9), are biomarkers used in clinical management of patients with gastrointestinal cancers. This study aimed to examine the prognostic role of these biomarkers in a patient population that started first-line chemotherapy for unresectable metastatic colorectal cancer (mCRC) in the NORDIC-VII study.METHODS: CEA and CA 19-9 were measured in serum samples from 545 patients obtained before the start of chemotherapy. Four hundred and ninety-four patients had detectable levels of carbohydrate antigen 19-9 (CA 19-9). RAS (exons 2-4) and BRAF (V600E) mutation status were available from 440 patients. Overall survival (OS) was estimated in patient groups defined by serum CEA or CA 19-9 levels using cut-off values of 5 µg/L and 35 kU/L, respectively, in the total population and in subgroups according to RAS and BRAF mutation status.RESULTS: For both CEA and CA 19-9, elevated serum levels were associated with reduced OS in adjusted analyses which included RAS and BRAF mutation status, baseline World Health Organization performance status, and levels of alkaline phosphatase and C-reactive protein. The negative prognostic information provided by an elevated CA 19-9 level was particularly marked in patients with BRAF mutation (hazard ratio = 4.35, interaction P = 0.003, in an adjusted model for OS).CONCLUSIONS: High baseline serum concentrations of CEA and CA 19-9 provide independent information of impaired prognosis in mCRC. In patients with BRAF-mutant tumours, elevated serum CA 19-9 may identify a subgroup with highly aggressive disease and could contribute to improving therapeutic decisions.

Published
2018

29. Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172)

Author

Schadendorf, Dirk Ascierto, Paolo Antonio Haanen, John B. A. G. and Espinosa, Enrique Demidov, Lev V. Garbe, Claus Lorigan, Paul Gogas, Helen Hoeller, Christoph Guren, Tormod Kyrre and Rorive, Andree Rutkowski, Piotr Munoz-Couselo, Eva Dummer, Reinhard Carneiro, Ana Hospers, Geke Grigoryeva, Elena Borisovna Bhore, Rafia Nathan, Paul

Published
2017

30. Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172)

Author

Ascierto, Paolo Antonio Demidov, Lev V. Garbe, Claus and Lorigan, Paul Gogas, Helen Hoeller, Christoph Haanen, John B. A. G. Espinosa, Enrique Guren, Tormod Kyrre and Munoz-Couselo, Eva Rorive, Andree Rutkowski, Piotr Dummer, Reinhard Carneiro, Ana Hospers, Geke Hermann, Frank and Jiang, Joel Schadendorf, Dirk Nathan, Paul D.

Published
2016

31. Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer

Author

Mezheyeuski, Artur, primary, Strell, Carina, additional, Hrynchyk, Ina, additional, Guren, Tormod Kyrre, additional, Dragomir, Anca, additional, Doroshenko, Tatyana, additional, Pashkova, Oksana, additional, Gorgun, Julia, additional, Ruksha, Kseniya, additional, Pfeiffer, Per, additional, Kure, Elin H., additional, Sorbye, Halfdan, additional, Edler, David, additional, Martling, Anna, additional, Glimelius, Bengt, additional, Östman, Arne, additional, and Portyanko, Anna, additional

Published
2017
Full Text
View/download PDF

32. Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).

Author

Schadendorf, Dirk, primary, Ascierto, Paolo Antonio, additional, Haanen, John B. A. G., additional, Espinosa, Enrique, additional, Demidov, Lev V., additional, Garbe, Claus, additional, Lorigan, Paul, additional, Gogas, Helen, additional, Hoeller, Christoph, additional, Guren, Tormod Kyrre, additional, Rorive, Andree, additional, Rutkowski, Piotr, additional, Muñoz-Couselo, Eva, additional, Dummer, Reinhard, additional, Carneiro, Ana, additional, Hospers, Geke, additional, Grigoryeva, Elena Borisovna, additional, Bhore, Rafia, additional, and Nathan, Paul, additional

Published
2017
Full Text
View/download PDF

33. Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study

Author

Guren, Tormod Kyrre, primary, Thomsen, Maria, additional, Kure, Elin H, additional, Sorbye, Halfdan, additional, Glimelius, Bengt, additional, Pfeiffer, Per, additional, Österlund, Pia, additional, Sigurdsson, Fridbjörn, additional, Lothe, Inger Marie Bowitz, additional, Dalsgaard, Astrid Marie, additional, Skovlund, Eva, additional, Christoffersen, Thoralf, additional, and Tveit, Kjell Magne, additional

Published
2017
Full Text
View/download PDF

34. Cetuximab in treatment of metastatic colorectal cancer : final survival analyses and extended RAS data from the NORDIC-VII study

Author

Guren, Tormod Kyrre, Thomsen, Maria, Kure, Elin H., Sorbye, Halfdan, Glimelius, Bengt, Pfeiffer, Per, Osterlund, Pia, Sigurdsson, Fridbjorn, Lothe, Inger Marie Bowitz, Dalsgaard, Astrid Marie, Skovlund, Eva, Christoffersen, Thoralf, Tveit, Kjell Magne, Guren, Tormod Kyrre, Thomsen, Maria, Kure, Elin H., Sorbye, Halfdan, Glimelius, Bengt, Pfeiffer, Per, Osterlund, Pia, Sigurdsson, Fridbjorn, Lothe, Inger Marie Bowitz, Dalsgaard, Astrid Marie, Skovlund, Eva, Christoffersen, Thoralf, and Tveit, Kjell Magne

Abstract

Background: The NORDIC-VII study is a randomised phase III trial of cetuximab plus continuous or intermittent fluorouracil, folinic acid, and oxaliplatin (Nordic FLOX) vs FLOX alone in first-line treatment of metastatic colorectal cancer. The present report presents an updated and final survival analysis with BRAF and extended RAS mutational status, 5 years after the primary analysis. Methods: A total of 566 patients were included in the intention-to-treat (ITT) population of the NORDIC-VII study. Updated survival status was obtained from 176 patients who were alive in the primary survival analyses. Samples from 223 tumours previously found to be KRAS (exon 2) and BRAF (V600E) wild-type, were re-analysed for KRAS (exons 3 and 4) and NRAS (exons 2-4) mutations. Results: Including the extended RAS analyses, RAS and BRAF mutational status was available from 457 patients (81% of the ITT population). RAS was mutated in 46% and BRAF in 12% of the tumours. RAS and BRAF, if mutated, were negative prognostic factors. The updated analyses confirmed the finding of the primary report that cetuximab did not provide any additional benefit when added to FLOX in patients with RAS/BRAF wild-type tumours, neither on progression-free nor overall survival. However, the outcomes in a subset of patients, which, after the first eight treatment cycles, received cetuximab alone, suggested a beneficial effect of cetuximab monotherapy. Conclusions: Adding cetuximab to Nordic FLOX did not provide any clinical benefit, but the data suggested an effect of cetuximab monotherapy in patients with RAS/BRAF wild-type tumours in the NORDIC-VII cohort. The data were compatible with a negative interaction between cetuximab and the Nordic FLOX chemotherapy backbone.

Published
2017
Full Text
View/download PDF

35. Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer

Author

Mezheyeuski, Artur, Lindh, Maja Bradic, Guren, Tormod Kyrre, Dragomir, Anca, Pfeiffer, Per, Kure, Elin H., Ikdahl, Tone, Skovlund, Eva, Corvigno, Sara, Strell, Carina, Pietras, Kristian, Ponten, Fredrik, Mulder, Jan, Qvortrup, Camilla, Portyanko, Anna, Tveit, Kjell Magne, Glimelius, Bengt, Sorbye, Halfdan, Östman, Arne, Mezheyeuski, Artur, Lindh, Maja Bradic, Guren, Tormod Kyrre, Dragomir, Anca, Pfeiffer, Per, Kure, Elin H., Ikdahl, Tone, Skovlund, Eva, Corvigno, Sara, Strell, Carina, Pietras, Kristian, Ponten, Fredrik, Mulder, Jan, Qvortrup, Camilla, Portyanko, Anna, Tveit, Kjell Magne, Glimelius, Bengt, Sorbye, Halfdan, and Östman, Arne

Abstract

Perivascular cells (PC) were recently implied as regulators of metastasis and immune cell activity. Perivascular heterogeneity in clinical samples, and associations with other tumor features and outcome, remain largely unknown. Here we report a novel method for digital quantitative analyses of vessel characteristics and PC, which was applied to two collections of human metastatic colorectal cancer (mCRC). Initial analyses identified marker-defined subsets of PC, including cells expressing PDGFR-beta or alpha-SMA or both markers. PC subsets were largely independently expressed in a manner unrelated to vessel density and size. Association studies implied specific oncogenic mutations in malignant cells as determinants of PC status. Semi-quantitative and digital-image-analyses-based scoring of the NORDIC-VII cohort identified significant associations between low expression of perivascular PDGFR-alpha and -beta and shorter overall survival. Analyses of the SPCRC cohort confirmed these findings. Perivascular PDGFR-alpha and -beta remained independent factors for survival in multivariate analyses. Overall, our study identified host vasculature and oncogenic status as determinants of tumor perivascular features. Perivascular PDGFR-alpha and -beta were identified as novel independent markers predicting survival in mCRC. The novel methodology should be suitable for similar analyses in other tumor collections.

Published
2016
Full Text
View/download PDF

36. Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer

Author

Thomsen, Maria, Kersten, Christian, Sorbye, Halfdan, Skovlund, Eva, Glimelius, Bengt, Pfeiffer, Per, Johansen, Julia S., Kure, Elin H., Ikdahl, Tone, Tveit, Kjell Magne, Christoffersen, Thoralf, Guren, Tormod Kyrre, Thomsen, Maria, Kersten, Christian, Sorbye, Halfdan, Skovlund, Eva, Glimelius, Bengt, Pfeiffer, Per, Johansen, Julia S., Kure, Elin H., Ikdahl, Tone, Tveit, Kjell Magne, Christoffersen, Thoralf, and Guren, Tormod Kyrre

Abstract

Objectives: The aim was to explore the prognostic significance of IL-6 and markers of systemic inflammatory response (SIR), in particular C-reactive protein (CRP), in metastatic colorectal cancer (mCRC) patients, in the total study population and according to RAS and BRAF mutation status. Results: High levels of pretreatment serum IL-6 or CRP were associated with impaired outcome, in terms of reduced PFS and OS. Patients with low versus high serum IL-6 levels had median OS of 26.0 versus 16.6 months, respectively (P < 0.001). Stratified according to increasing CRP levels, median OS varied from 24.3 months to 12.3 months, (P < 0.001). IL-6 and CRP levels affected overall prognosis also in adjusted analyses. The effect of IL-6 was particularly pronounced in patients with BRAF mutation (interaction P = 0.004). Materials and Methods: IL-6 and CRP were determined in pre-treatment serum samples from 393 patients included in the NORDIC-VII trial, in which patients with mCRC received first line treatment. The effect of serum IL-6 and CRP on progression-free survival (PFS) and overall survival (OS) was estimated. Conclusions: High baseline serum consentrations of IL-6 or CRP were associated with impaired prognosis in mCRC. IL-6 and CRP give independent prognostic information in addition to RAS and BRAF mutation status.

Published
2016
Full Text
View/download PDF

37. Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer

Author

Thomsen, Maria, primary, Kersten, Christian, additional, Sorbye, Halfdan, additional, Skovlund, Eva, additional, Glimelius, Bengt, additional, Pfeiffer, Per, additional, Johansen, Julia S., additional, Kure, Elin H., additional, Ikdahl, Tone, additional, Tveit, Kjell Magne, additional, Christoffersen, Thoralf, additional, and Guren, Tormod Kyrre, additional

Published
2016
Full Text
View/download PDF

38. Abstract C38: Marker-defined perivascular cells predict prognosis and response to treatment

Author

corvigno, Sara, primary, mezheyeuski, artur, additional, Frodin, Magnus, additional, Lindh, Maja Bradic, additional, Guren, Tormod Kyrre, additional, Pfeiffer, Per, additional, Kure, H. Elin, additional, Ikdahl, Tone, additional, Skovlund, Eva, additional, Tveit, Kjell Magne, additional, Pietras, Kristian, additional, Portyanko, Anna, additional, Hrynchyk, Ina, additional, Edler, David, additional, Dragomir, Anca, additional, Ponten, friedrik, additional, Mulder, Jan, additional, Qvortrup, Camilla, additional, Hallström, Maria, additional, Öhrling, Katarina, additional, Wisman, G. Bea A., additional, Åvall-Lundqvist, Elisabeth, additional, Johansson, Martin, additional, Harmenberg, Ulrika, additional, Nijman, Hans, additional, Sandström, Per, additional, Dahlstrand, Hanna, additional, Sorbye, Halfdan, additional, Gimelius, Bengt, additional, Zee, Ate Van Der, additional, Egevad, Lars, additional, and Östman, Arne, additional

Published
2016
Full Text
View/download PDF

39. Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer

Author

Mezheyeuski, Artur, primary, Lindh, Maja Bradic, additional, Guren, Tormod Kyrre, additional, Dragomir, Anca, additional, Pfeiffer, Per, additional, Kure, Elin H., additional, Ikdahl, Tone, additional, Skovlund, Eva, additional, Corvigno, Sara, additional, Strell, Carina, additional, Pietras, Kristian, additional, Ponten, Fredrik, additional, Mulder, Jan, additional, Qvortrup, Camilla, additional, Portyanko, Anna, additional, Tveit, Kjell Magne, additional, Glimelius, Bengt, additional, Sorbye, Halfdan, additional, and Östman, Arne, additional

Published
2016
Full Text
View/download PDF

40. Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC).

Author

Tabernero, Josep, primary, Geel, Robin Van, additional, Guren, Tormod Kyrre, additional, Yaeger, Rona D., additional, Spreafico, Anna, additional, Faris, Jason Edward, additional, Yoshino, Takayuki, additional, Yamada, Yasuhide, additional, Kim, Tae Won, additional, Bendell, Johanna C., additional, Schuler, Martin H., additional, Lenz, Heinz-Josef, additional, Eskens, Ferry, additional, Desai, Jayesh, additional, Hochster, Howard S., additional, Avsar, Emin, additional, Demuth, Tim, additional, Sandor, Victor, additional, Elez, Elena, additional, and Schellens, Jan H.M., additional

Published
2016
Full Text
View/download PDF

41. Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172).

Author

Ascierto, Paolo Antonio, primary, Demidov, Lev V., additional, Garbe, Claus, additional, Lorigan, Paul, additional, Gogas, Helen, additional, Hoeller, Christoph, additional, Haanen, John B. A. G., additional, Espinosa, Enrique, additional, Guren, Tormod Kyrre, additional, Muñoz-Couselo, Eva, additional, Rorive, Andree, additional, Rutkowski, Piotr, additional, Dummer, Reinhard, additional, Carneiro, Ana, additional, Hospers, Geke, additional, Hermann, Frank, additional, Jiang, Joel, additional, Schadendorf, Dirk, additional, and Nathan, Paul D., additional

Published
2016
Full Text
View/download PDF

42. FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab

Author

Kjersem, Janne Beathe, Skovlund, Eva, Ikdahl, Tone, Guren, Tormod Kyrre, Kersten, Christian, Dalsgaard, Astrid Marie, Yilmaz, Mette Karen, Fokstuen, Tone, Tveit, Magne Kjell, and Kure, Elin H.

Subjects
VDP::Medisinske fag: 700::Helsefag: 800::Epidemiologi medisinsk og odontologisk statistikk: 803, VDP::Midical sciences: 700::Health sciences: 800::Epidemiology, medical and dental statistics: 803
Abstract

Background Polymorphisms of genes encoding the Fcy receptors (Fc fragment of IgG receptor 2A (FCGR2A) and 3A (FCGR3A)), which influence their affinity for the Fc fragment, have been linked to the pharmacodynamics of monoclonal antibodies. Most studies have been limited by small samples sizes and have reported inconsistent associations between the FCGR2A and the FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer (mCRC) patients treated with cetuximab. We investigated the association of these polymorphisms and clinical outcome in a large cohort of mCRC patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin (Nordic FLOX) +/- cetuximab in the NORDIC-VII study (NCT00145314). Methods 504 and 497 mCRC patients were evaluable for the FCGR2A and FCGR3A genotyping, respectively. Genotyping was performed on TaqMan ABI HT 7900 (Applied Biosystems, Foster City, CA, USA) with pre-designed SNP genotyping assays for FCGR2A (rs1801274) and FCGR3A (rs396991). Results The response rate for patients with the FCGR2A R/R genotype was significantly increased when cetuximab was added to Nordic FLOX (31% versus 53%, interaction P?=?0.03), but was not significantly different compared to the response rate of patients with the FCGR2A H/H or H/R genotypes given the same treatment. A larger increase in response rate with the addition of cetuximab to Nordic FLOX in patients with KRAS mutated tumors and the FCGR2A R/R genotype was observed (19% versus 50%, interaction P?=?0.04). None of the FCGR3A polymorphisms were associated with altered response when cetuximab was added to Nordic FLOX (interaction P?=?0.63). Neither of the FCGR polymorphisms showed any significant associations with progression-free survival or overall survival. Conclusion Patients with KRAS mutated tumors and the FCGR2A R/R polymorphism responded poorly when treated with chemotherapy only, and experienced the most benefit of the addition of cetuximab in terms of response rate.

Published
2014

43. Abstract B141: Combining the telomerase peptide cancer vaccine UV1 with CTLA-4 blockade in patients with metastatic malignant melanoma: Proof of principle and early clinical reports from a phase I/IIa trial

Author

Aamdal, Elin, primary, Guren, Tormod Kyrre, additional, Suso, Else Marit Inderberg, additional, Kvalheim, Gunnar, additional, Kyte, Jon Amund, additional, Arnesen, Øyvind Kongstun, additional, Aamdal, Steinar, additional, and Gaudernack, Gustav, additional

Published
2016
Full Text
View/download PDF

44. C-reactive protein and interleukin-6 as markers of systemic inflammatory response and as prognostic factors for metastatic colorectal cancer. Data from the randomized phase III NORDIC-VII study

Author

Thomsen, Maria, Kersten, Christian, Sorbye, Halfdan, Skovlund, Eva, Ikdahl, Tone, Johansen, Julia S., Pfeiffer, Per, Glimelius, Bengt, Tveit, Kjell Magne, Guren, Tormod Kyrre, Thomsen, Maria, Kersten, Christian, Sorbye, Halfdan, Skovlund, Eva, Ikdahl, Tone, Johansen, Julia S., Pfeiffer, Per, Glimelius, Bengt, Tveit, Kjell Magne, and Guren, Tormod Kyrre

Published
2015

45. C-reactive protein and interleukin-6 as markers of systemic inflammatory response and as prognostic factors for metastatic colorectal cancer. Data from the randomized phase III NORDIC-VII study.

Author

Thomsen, Maria, primary, Kersten, Christian, additional, Sorbye, Halfdan, additional, Skovlund, Eva, additional, Ikdahl, Tone, additional, Johansen, Julia S., additional, Pfeiffer, Per, additional, Glimelius, Bengt, additional, Tveit, Kjell Magne, additional, and Guren, Tormod Kyrre, additional

Published
2015
Full Text
View/download PDF

46. Digitalized multiparametric analyses of tumor stroma for identification of low perivascular PDGFBR expression and low vessel density as independent prognosis markers for stage IV CRC

Author

Mezheyeuski, Artur, Lindh, Maja Bradic, Glimelius, Bengt, Pfeiffer, Per, Kure, Elin, Ikdahl, Tone, Skovlund, Eva, Sorbye, Halfdan, Tvelt, Kjell Magna, Pletras, Kristian, Birgisson, Helgi, Mulder, Jan, Guren, Tormod Kyrre, Portyanko, Anna, Ostman, Arne, Mezheyeuski, Artur, Lindh, Maja Bradic, Glimelius, Bengt, Pfeiffer, Per, Kure, Elin, Ikdahl, Tone, Skovlund, Eva, Sorbye, Halfdan, Tvelt, Kjell Magna, Pletras, Kristian, Birgisson, Helgi, Mulder, Jan, Guren, Tormod Kyrre, Portyanko, Anna, and Ostman, Arne

Published
2014

47. Benefit of EGFR-inhibition therapy for metastatic colorectal cancer patients with KRAS-mutated tumors and high plasma TIMP-I level : Results from the NORDIC VII study

Author

Brunner, Nils, Tarpgaard, Line Schmidt, Christensen, Ib Jarle, Moreira, Jose, Guren, Tormod Kyrre, Glimelius, Bengt, Sorby, Halfdan, Ikdahl, Tone, Kure, Elin, Tveit, Kjell Magne, Nielsen, Hans Jorgen, Pfeiffer, Per, Brunner, Nils, Tarpgaard, Line Schmidt, Christensen, Ib Jarle, Moreira, Jose, Guren, Tormod Kyrre, Glimelius, Bengt, Sorby, Halfdan, Ikdahl, Tone, Kure, Elin, Tveit, Kjell Magne, Nielsen, Hans Jorgen, and Pfeiffer, Per

Published
2014

49. Benefit of EGFR-inhibition therapy for metastatic colorectal cancer patients with KRAS-mutated tumors and high plasma TIMP-1 level: Results from the NORDIC VII study.

Author

Brunner, Nils, primary, Tarpgaard, Line Schmidt, additional, Christensen, Ib Jarle, additional, Moreira, Jose, additional, Guren, Tormod Kyrre, additional, Glimelius, Bengt, additional, Sorby, Halfdan, additional, Ikdahl, Tone, additional, Kure, Elin, additional, Tveit, Kjell Magne, additional, Nielsen, Hans Jørgen, additional, and Pfeiffer, Per, additional

Published
2014
Full Text
View/download PDF

50. Digitalized multiparametric analyses of tumor stroma for identification of low perivascular PDGFBR expression and low vessel density as independent prognosis markers for stage IV CRC.

Author

Mezheyeuski, Artur, primary, Lindh, Maja Bradic, additional, Glimelius, Bengt, additional, Pfeiffer, Per, additional, Kure, Elin, additional, Ikdahl, Tone, additional, Skovlund, Eva, additional, Sorbye, Halfdan, additional, Tveit, Kjell Magne, additional, Pietras, Kristian, additional, Birgisson, Helgi, additional, Mulder, Jan, additional, Guren, Tormod Kyrre, additional, Portyanko, Anna, additional, and Ostman, Arne, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results